Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051755 | 0.86 | MEN1 (0.49) | MEN1KMT2AMMP8CASP1MAPT | |
| SCHEMBL4061773 | 0.86 | MEN1 (0.49) | MEN1KMT2AMMP8CASP1MAPT | |
| SCHEMBL27590464 | 0.77 | MMP8 (0.57) | MEN1KMT2AMMP8LMNAMAPK1 | |
| SCHEMBL3266292 | 0.77 | MMP8 (0.57) | MEN1KMT2AMMP8LMNAMAPK1 | |
| SCHEMBL4297584 | 0.77 | MMP8 (0.57) | MEN1KMT2AMMP8LMNAMAPK1 | |
| SCHEMBL279960 | 0.77 | MMP8 (0.57) | MEN1KMT2AMMP8LMNAMAPK1 | |
| SCHEMBL5245988 | 0.76 | CASP1 (0.64) | MEN1KMT2AMMP8CASP1MAPT | |
| SCHEMBL28929530 | 0.75 | MMP8 (0.56) | MEN1KMT2AMMP8LMNAMAPK1 | |
| SCHEMBL28929528 | 0.75 | MMP8 (0.56) | MEN1KMT2AMMP8LMNAMAPK1 | |
| SCHEMBL29117706 | 0.74 | ALDH1A1 (0.54) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | THE INSTITUTE OF MOLECULAR MEDICINE (IN) | 2011-03-10 | — | — | US | disclosed |
| WO-2009091324-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS | CHATTOPADHYAYA JYOTI (SE) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | NQO1, NQO2, NDUFV1 | MEN1 1176/4885KMT2A 3953/4885MMP8 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.